261 related articles for article (PubMed ID: 22995028)
1. Two-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.
Yamashita A; Shiraga F; Shiragami C; Shirakata Y; Fujiwara A
Am J Ophthalmol; 2013 Jan; 155(1):96-102.e1. PubMed ID: 22995028
[TBL] [Abstract][Full Text] [Related]
2. One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.
Yamashita A; Shiraga F; Shiragami C; Ono A; Tenkumo K
Am J Ophthalmol; 2010 Mar; 149(3):465-71.e1. PubMed ID: 20042180
[TBL] [Abstract][Full Text] [Related]
3. Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Sagong M; Lim S; Chang W
Am J Ophthalmol; 2012 May; 153(5):873-882.e2. PubMed ID: 22265146
[TBL] [Abstract][Full Text] [Related]
4. Five-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy.
Kang HM; Kim YM; Koh HJ
Am J Ophthalmol; 2013 Mar; 155(3):438-447.e1. PubMed ID: 23218705
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
Jain P; Anantharaman G; Gopalakrishnan M; Goyal A
Indian J Ophthalmol; 2018 Aug; 66(8):1119-1127. PubMed ID: 30038155
[TBL] [Abstract][Full Text] [Related]
6. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab.
Tomita K; Tsujikawa A; Yamashiro K; Ooto S; Tamura H; Otani A; Nakayama Y; Yoshimura N
Am J Ophthalmol; 2012 Jan; 153(1):68-80.e1. PubMed ID: 21907965
[TBL] [Abstract][Full Text] [Related]
7. Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy.
Ricci F; Calabrese A; Regine F; Missiroli F; Ciardella AP
Retina; 2012 Jul; 32(7):1280-8. PubMed ID: 22218148
[TBL] [Abstract][Full Text] [Related]
8. Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy.
Otani A; Sasahara M; Yodoi Y; Aikawa H; Tamura H; Tsujikawa A; Yoshimura N
Am J Ophthalmol; 2007 Jul; 144(1):7-14. PubMed ID: 17467649
[TBL] [Abstract][Full Text] [Related]
9. One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
Matsumiya W; Honda S; Otsuka K; Miki A; Nagai T; Imai H; Kusuhara S; Nakamura M
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):541-548. PubMed ID: 27687988
[TBL] [Abstract][Full Text] [Related]
10. Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy: results after 3 years of follow-up.
Leal S; Silva R; Figueira J; Cachulo ML; Pires I; de Abreu JR; Cunha-Vaz JG
Retina; 2010 Sep; 30(8):1197-205. PubMed ID: 20827139
[TBL] [Abstract][Full Text] [Related]
11. Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: two years of follow-up.
Lee YA; Yang CH; Yang CM; Ho TC; Lin CP; Huang JS; Chen MS
Am J Ophthalmol; 2012 Nov; 154(5):872-880.e2. PubMed ID: 22831838
[TBL] [Abstract][Full Text] [Related]
12. Extensive submacular haemorrhage in polypoidal choroidal vasculopathy managed by sequential gas displacement and photodynamic therapy: a pilot study of one-year follow up.
Chan WM; Liu DT; Lai TY; Li H; Tong JP; Lam DS
Clin Exp Ophthalmol; 2005 Dec; 33(6):611-8. PubMed ID: 16402954
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.
Gomi F; Sawa M; Wakabayashi T; Sasamoto Y; Suzuki M; Tsujikawa M
Am J Ophthalmol; 2010 Jul; 150(1):48-54.e1. PubMed ID: 20609707
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal ranibizumab combined with verteporfin photodynamic therapy for treating polypoidal choroidal vasculopathy.
Lee YH; Lee EK; Shin KS; Lee KM; Kim JY
Retina; 2011; 31(7):1287-93. PubMed ID: 21386762
[TBL] [Abstract][Full Text] [Related]
15. Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy.
Gemmy Cheung CM; Yeo I; Li X; Mathur R; Lee SY; Chan CM; Wong D; Wong TY
Am J Ophthalmol; 2013 Feb; 155(2):295-304.e1. PubMed ID: 23111181
[TBL] [Abstract][Full Text] [Related]
16. 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy.
Wong IY; Shi X; Gangwani R; Zhao P; Iu LP; Li Q; Ng A; Li X
BMC Ophthalmol; 2015 Jun; 15():66. PubMed ID: 26122636
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy.
Lai TY; Lee GK; Luk FO; Lam DS
Retina; 2011 Sep; 31(8):1581-8. PubMed ID: 21610566
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of combined photodynamic therapy and intravitreal bevacizumab injection versus photodynamic therapy alone in polypoidal choroidal vasculopathy.
Kim SJ; Yu HG
Retina; 2011 Oct; 31(9):1827-34. PubMed ID: 21734621
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series.
Chan WM; Lam DS; Lai TY; Liu DT; Li KK; Yao Y; Wong TH
Ophthalmology; 2004 Aug; 111(8):1576-84. PubMed ID: 15288991
[TBL] [Abstract][Full Text] [Related]
20. Improvement of angiographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months.
Hikichi T; Ohtsuka H; Higuchi M; Matsushita T; Ariga H; Kosaka S; Matsushita R; Takami K
Am J Ophthalmol; 2010 Nov; 150(5):674-682.e1. PubMed ID: 20691424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
